SARCOIDOSIS DANIEL CULVER, DO DIRECTOR, INTERSTITIAL LUNG DISEASE PROGRAM CLEVELAND CLINIC CLEVELAND, OH Daniel Culver received his BS from Ohio State University with degrees in Biology and English. He received his Doctor of Osteopathy from Heritage Ohio University College of Osteopathic Medicine, and then completed training at Southpointe Hospital and Cleveland Clinic for Internal Medicine and Pulmonary-Critical Care Medicine. He is the director of the Interstitial Lung Disease Program at Cleveland Clinic, Chair of the Scientific Advisory Board for the Foundation for Sarcoidosis Research, and the President- elect of the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG). He is the Research Officer for the Respiratory Institute at Cleveland Clinic. His interests include clinical trials, novel endpoint development, and newer therapies. In the sarcoidosis arena, he has special interests in cardiac sarcoidosis and small fiber neuropathy related to sarcoidosis. Outside of medicine, he stays busy with his wife and 3 children, and he is currently preparing for the Marine Corps Marathon at the time of this writing. SATURDAY, MARCH 16, 2019 11:15 AM
29
Embed
SARCOIDOSIS - namdrc.org Culver Saturday 3-16-19.pdfsarcoidosis arena, he has special interests in cardiac sarcoidosis and small fiber neuropathy related to sarcoidosis. Outside of
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
SARCOIDOSIS DANIEL CULVER, DO DIRECTOR, INTERSTITIAL LUNG DISEASE PROGRAM CLEVELAND CLINIC CLEVELAND, OH
Daniel Culver received his BS from Ohio State University with degrees in Biology and English. He received his Doctor of Osteopathy from Heritage Ohio University College of Osteopathic Medicine, and then completed training at Southpointe Hospital and Cleveland Clinic for Internal Medicine and Pulmonary-Critical Care Medicine. He is the director of the Interstitial Lung Disease Program at Cleveland Clinic, Chair of the Scientific Advisory Board for the Foundation for Sarcoidosis Research, and the President-elect of the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG). He is the Research Officer for the Respiratory Institute at Cleveland Clinic. His interests include clinical trials, novel endpoint development, and newer therapies. In the sarcoidosis arena, he has special interests in cardiac sarcoidosis and small fiber neuropathy related to sarcoidosis. Outside of medicine, he stays busy with his wife and 3 children, and he is currently preparing for the Marine Corps Marathon at the time of this writing.
SATURDAY, MARCH 16, 2019 11:15 AM
1
SARCOIDOSIS
Sarcoidosis disclosures
• Clinical trials/consulting– Celgene– aTyr– Mallinkrodt– Johnson & Johnson
• Research support– Foundation for Sarcoidosis Research– NHLBI– Ann Theodore Foundation– Mallinkrodt
2
Which is false about the epidemiology of sarcoidosis?
1. More common in African-Americans
2. More common in females
3. Diagnosed before age 50 in most
4. Mortality rates are rising in the US
5. Prevalence is highest in the Southeast and lowest in the West
3
Mortality in Swedish sarcoidosis patients vs general population
Non-hispanic Males: Numbers of Deaths and Age-adjusted Mortality Rates per 1,000,000 Men
0
50
100
150
200
250
300
350
0
2
4
6
8
10
12
14
16
18
20
Deaths: Non- hispanic White Males
Deaths: Non- hispanic Black Males
Mortality Rates: Non- hispanic White Males
Mortality Rates: Non- hispanic Black Males
4
Sarcoidosis less common in the West
Baughman RP. Ann Am Thorac Soc 2016
Sarcoidosis in the US
2010-2013 Optum Database
Baughman RP. Ann Am Thorac Soc 2016
5
Female predilection
Most patients are >55 at the time of diagnosis now
Baughman RP. Ann Am Thorac Soc 2016
6
Mortality in Swedish sarcoidosis patients vs age
Rossides M. Eur Respir J 2018
Who is at risk for mortality in pulmonary sarcoidosis?
Walsh SLF. Lancet Respir Med 2015
7
Validation cohort test performance
n=252
Fibrotic sarcoidosis is not UIP
8
Is mortality the best vantage point?
Complications of fibrosis
9
Chest CT pattern correlates with exercise capacity
Lopes AJ. Lung 2011
Sarcoidosis burden in a US registry
Hospitalization
Large financial impact
n=2318
10
Sarcoidosis penumbra
Lazar CA. SRCCM 2010
Cumulative risk of steroid complications
Other covariatesAge/yr 1.02 (1.00-1.04)
Pre-existing disease 2.27 (1.33-3.89)
HR: 2.37 (1.34-4.17)
Duration of steroids ( per month)1.023 (1.013-1.033)
Cumulative dose ( per gram)1.038 (1.019-1.056)
Khan NA. Respir Med 2017
11
Which of the following is the least common cause of exercise limitation in sarcoidosis?
1. Airways hyper-reactivity
2. Cardiac sarcoidosis
3. Pulmonary hypertension
4. Large airways stenosis from endobronchial disease
5. Myopathy
12
Multifaceted dyspnea of sarcoidosis
Dyspneic sarcoidosispatient
Anemia
Cardiac sarcoidosis
Diaphragm myopathy
Pulmonary HTN
Obesity
Deconditioning Airways stenosisBronchospasm
Asthmatic symptoms are common
• Endobronchial involvement in up to 75%
• Obstructive physiology in up to half
• Positive methacholine challenge test 21%
• May respond to inhaled corticosteroids and bronchodilators
• Proximal airway stenosis in 3-5 % RUL
13
Unusual causes of dyspnea
Sarcoidosis Associated PAH—membership in WHO Group 5
LV diseaseHypoxia
Portopulmonary HTN
Elevated pulmonary pressure
14
Granuloma distribution and pulmonary hypertension
Diaz-Guzman E. Clin Chest Med 2008
Pulmonary hypertension in sarcoidosis
0
10
20
30
40
50
60
70
80
Per
cent
wit
h P
ulm
onar
y
Hyp
erte
nsio
n
Kyoto Detroit Milan New York Cincinnati Transplant
All patients Only Dyspneic Patients
Baughman RP, Culver DA, Judson MA. AJRCCM 2011
15
Pulmonary hypertension in a large international registry
Baughman RP. Resp Med 2018
n=176
Do clinical markers predict SAPH?
Baughman RP. Resp Med 2018
16
Survival from time of RHC
Group123
0 500 1000 1500 2000 2500
100
90
80
70
60
50
40
30
Days from Catheterization
Sur
viva
l pro
babi
lity
(%)
Normal PAPH-LVDSAPAH
Baughman RP. Chest 2010
p<0.02
RCT of bosentan for SAPH
p=0.01
p=0.01
Baughman RP. Chest 2014
17
Shlobin OA. In press
6MWT and FEV1/FVC ratio were the strongest predictors of survival
Respiratory muscle weakness in sarcoidosis
Kabitz HJ. Chest 2006
18
Marcellis RG. ERJ 2011 Spruit MA. Thorax 2005
Muscle weakness relates to other variables affecting QOL
6MWD Hand grip Extensor Quadriceps PT
HPT Pimax
Men -0.25 -0.25 -0.29 -0.17 -0.36 0.24
Women -0.12 -0.21 -0.30 -0.04 -0.043 0.051
Spruit MA Thorax 2005
Steroids are associated with muscle weakness in sarcoidosis
19
Which is true about cardiac sarcoidosis?
1. Most common presentation is ventricular dysrhythmias
2. Most common in black females
3. Cardiac FDG-PET is the diagnostic test of choice
4. Serum ACE level is usually normal
5. All are true
20
Which is true about cardiac sarcoidosis?
1. Most common presentation is ventricular dysrhythmias
2. Most common in black females
3. Cardiac FDG-PET is the diagnostic test of choice
4. Serum ACE level is usually normal
5. All are true
Frequency of cardiac sarcoidosis
21
Prevalence of cardiac abnormalities in various series
AV block 26-62%
Bundle branch block 12-61%
Cardiomyopathy 10-30%
Ventricular tachycardia 2-42%
Supraventricular tachycardia
0-15%
Kim JS. Am Heart J. 2009
I
MRI is the most specific test for evaluating possible CS
22
Cardiac PET scan assesses scar and inflammation
Who is at higher risk for cardiac involvement
• White males—FSR registry– O.R. 1.4 for whites vs blacks
– O.R. 1.8 for males vs females
• Neurologic and ocular disease
• Multisystem disease
• Chronic disease
• Ocular-cutaneous-CNS-cardiac cluster
Lower EE. Arch Intern Med 1997 Rybicki BA. Genes Immun 2007Inoue Y. PlosOne 2015 Schupp JC. Eur Respir J 2018
23
How can we arrive at a diagnosis?
“The diagnosis is established whenclinicoradiological findings are supportedby histological evidence of non-caseatingepithelioid cell granulomas. Granulomasof known causes and local sarcoidreactions must be excluded…..”
ATS Statement on Sarcoidosis. Am J Resp Crit Care Med 1999
Does bronchoscopy have a role in the diagnosis of extrapulmonary sarcoidosis?
17 patients with mediastinal LN <10 mm
24
Typical chest CT features may be diagnostic
56%
76%
54%
• 66% of sarcoidosis diagnosed with high confidence (>75% certain)• 87% of sarcoidosis diagnosed as leading choice